{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"title":"Complete Response"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Complete Response unconfirmed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"ORR at EOI therapy was defined as the percentage of particpants with either a CR, CR unconfirmed or PR at the EOI visit, as determined by the investigator and according to the guidelines used at the site.","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of induction therapy (up to approximately 6 months)","title":"Objective Response Rate (ORR) at the End of Induction (EOI) Therapy","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}